NASDAQ : TECH
Bio-Techne Corporation — Key statistics
Healthcare · Biotechnology · United States
Last price 72.71 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.40B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.39B |
| Enterprise Value | 11.42B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | Aug 24, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 156.82M |
| Shares Outstanding | 156.82M |
| Shares Change (YoY) | -1.70% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 111.62% |
| Float | 156.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 62.64 |
| Forward PE | 35.68 |
| PS Ratio | 9.38 |
| Forward PS | 9.02 |
| PB Ratio | 5.38 |
| P/TBV Ratio | 13.74 |
| P/FCF Ratio | 43.29 |
| P/OCF Ratio | 39.01 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 62.79 |
| EV / Sales | 9.40 |
| EV / EBITDA | 34.17 |
| EV / EBIT | 41.59 |
| EV / FCF | 43.38 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.55 |
| Quick Ratio | 2.94 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.81 |
| Debt / FCF | 1.10 |
| Interest Coverage | 28.51 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 9.03% |
| Return on Assets (ROA) | 6.67% |
| Return on Invested Capital (ROIC) | 9.66% |
| Return on Capital Employed (ROCE) | 11.33% |
| Weighted Average Cost of Capital (WACC) | 11.15% |
| Revenue Per Employee | $405,013 |
| Profits Per Employee | $60,613 |
| Employee Count | 3,000 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.13 |
Taxes
| Measure | Value |
|---|
| Income Tax | 58.82M |
| Effective Tax Rate | 24.44% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.30 |
| 52-Week Price Change | +17.16% |
| 50-Day Moving Average | 72.45 |
| 200-Day Moving Average | 63.16 |
| Relative Strength Index (RSI) | 57.20 |
| Average Volume (20 Days) | 2,796,607 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.55M |
| Short Previous Month | 7.39M |
| Short % of Shares Out | 4.82% |
| Short % of Float | 4.84% |
| Short Ratio (days to cover) | 2.42 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.22B |
| Gross Profit | 804.88M |
| Operating Income | 274.55M |
| Pretax Income | 240.68M |
| Net Income | 181.84M |
| EBITDA | 334.11M |
| EBIT | 274.55M |
| Earnings Per Share (EPS) | $1.16 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 265.48M |
| Total Debt | 289.09M |
| Net Cash | -23.61M |
| Net Cash Per Share | -$0.15 |
| Equity (Book Value) | 2.11B |
| Book Value Per Share | 13.51 |
| Working Capital | 580.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 292.07M |
| Capital Expenditures | -28.85M |
| Depreciation & Amortization | 59.56M |
| Net Borrowing | -146.00M |
| Free Cash Flow | 263.22M |
| FCF Per Share | $1.68 |
Margins
| Measure | Value |
|---|
| Gross Margin | 66.24% |
| Operating Margin | 22.60% |
| Pretax Margin | 19.81% |
| Profit Margin | 14.97% |
| EBITDA Margin | 27.50% |
| EBIT Margin | 22.60% |
| FCF Margin | 21.66% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 27.59% |
| FCF Payout Ratio | 19.06% |
| Buyback Yield | 1.70% |
| Shareholder Yield | 2.14% |
| Earnings Yield | 1.60% |
| FCF Yield | 2.31% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $70.50 |
| Price Target Difference | -2.97% |
| Analyst Consensus | Hold |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 8.24% |
| EPS Growth Forecast (3Y) | 9.78% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |